Analyst Justin Walsh from JonesTrading reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) and keeping the price target at $9.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Justin Walsh has given his Buy rating due to a combination of factors related to the promising developments in Actinium Pharmaceuticals’ ATNM-400. The preclinical data presented at the SNMMI Annual Meeting highlighted ATNM-400’s potential in treating advanced prostate cancer, particularly in models resistant to current treatments. The compound demonstrated significant anti-tumor activity and favorable tumor uptake, surpassing existing therapies like Lu-177-PSMA-617 and Ac-225-PSMA-617 in preclinical models.
Moreover, the rapid clearance of ATNM-400 from healthy tissues suggests a potentially safer profile, which is crucial for patient outcomes. Although further information is needed to fully understand the molecular target and potential market opportunity, the current data supports the potential of ATNM-400 as a promising therapeutic option. These factors collectively underpin Walsh’s Buy rating and the $9 price target for Actinium Pharmaceuticals.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $4.00 price target.